/KPTI
KPTI Stock - Karyopharm Therapeutics Inc.
Healthcare|BiotechnologyNASDAQ
$6.94+8.95%
+$0.57 (+8.95%) • Dec 19
89
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.94
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+104.2%upside
Target: $14.17
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for KPTI
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$6.87 – $7.01
TARGET (TP)$14.17
STOP LOSS$6.38
RISK/REWARD1:12.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.23
52W High$12.45
52W Low$3.51
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $145.24M | $146.03M | $157.07M | $209.82M | $108.08M |
| Gross Profit | $139.23M | $141.09M | $151.86M | $206.42M | $105.38M |
| Gross Margin | 95.9% | 96.6% | 96.7% | 98.4% | 97.5% |
| Operating Income | $-119,443,000 | $-129,540,000 | $-142,202,000 | $-98,271,000 | $-171,850,000 |
| Net Income | $-76,422,000 | $-143,099,000 | $-165,291,000 | $-124,088,000 | $-196,273,000 |
| Net Margin | -52.6% | -98.0% | -105.2% | -59.1% | -181.6% |
| EPS | $-9.41 | $-18.79 | $-30.28 | $-24.75 | $-40.87 |
Company Overview
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
3
75%
Hold / Neutral
1
25%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
3 Bullish1 Neutral/Bearish
Price Targets
$15
Average Target
↑ 116.1% Upside
Now
$8
Low
$15
Average
$27
High
Based on 4 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 13th 2025 | H.C. Wainwright | Upgrade | Buy | $15 |
| July 16th 2025 | H.C. Wainwright | Downgrade | Neutral | - |
| July 11th 2025 | H.C. Wainwright | Resumed | Buy | $27 |
| January 19th 2023 | Piper Sandler | Initiation | Overweight | $8 |
| November 4th 2022 | RBC Capital Mkts | Upgrade | Outperform | $10← $7 |
Earnings History & Surprises
KPTIBeat Rate
67%
Last 18 quarters
Avg Surprise
+15.4%
EPS vs Estimate
Beats / Misses
12/6
Last 12 quarters
Latest EPS
$-3.82
Q4 2025
EPS Surprise History
Q1 24
-24.1%
$-5.40vs$-4.35
Q2 24
+3.0%
$-4.80vs$-4.95
Q3 24
+31.0%
$-3.00vs$-4.35
Q4 24
+3.7%
$-3.90vs$-4.05
Q1 25
+7.7%
$-3.60vs$-3.90
Q2 25
+34.2%
$-2.77vs$-4.21
Q3 25
-13.7%
$-4.32vs$-3.80
Q4 25
-10.1%
$-3.82vs$-3.47
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Feb 18, 2026 | $-2.26 | — | — | — |
Q4 2025 | Nov 3, 2025 | $-3.47 | $-3.82 | -10.1% | ✗ MISS |
Q3 2025 | Aug 11, 2025 | $-3.80 | $-4.32 | -13.7% | ✗ MISS |
Q2 2025 | May 12, 2025 | $-4.21 | $-2.77 | +34.2% | ✓ BEAT |
Q1 2025 | Feb 19, 2025 | $-3.90 | $-3.60 | +7.7% | ✓ BEAT |
Q4 2024 | Nov 5, 2024 | $-4.05 | $-3.90 | +3.7% | ✓ BEAT |
Q3 2024 | Aug 6, 2024 | $-4.35 | $-3.00 | +31.0% | ✓ BEAT |
Q2 2024 | May 8, 2024 | $-4.95 | $-4.80 | +3.0% | ✓ BEAT |
Q1 2024 | Feb 29, 2024 | $-4.35 | $-5.40 | -24.1% | ✗ MISS |
Q4 2023 | Nov 2, 2023 | $-4.20 | $-4.50 | -7.1% | ✗ MISS |
Q3 2023 | Aug 2, 2023 | $-5.10 | $-4.35 | +14.7% | ✓ BEAT |
Q2 2023 | May 4, 2023 | $-5.10 | $-4.50 | +11.8% | ✓ BEAT |
Q1 2023 | Feb 15, 2023 | $-5.10 | $-6.45 | -26.5% | ✗ MISS |
Q4 2022 | Nov 3, 2022 | $-8.40 | $-6.75 | +19.6% | ✓ BEAT |
Q3 2022 | Aug 4, 2022 | $-9.45 | $-9.30 | +1.6% | ✓ BEAT |
Q2 2022 | May 5, 2022 | $-9.45 | $-7.95 | +15.9% | ✓ BEAT |
Q1 2022 | Feb 8, 2022 | $-6.00 | $6.90 | +215.0% | ✓ BEAT |
Q4 2021 | Nov 3, 2021 | $-10.19 | $-10.34 | -1.5% | ✗ MISS |
Q3 2021 | Aug 5, 2021 | $-10.79 | $-10.64 | +1.4% | ✓ BEAT |
Latest News
RBC Capital Maintains Outperform on Karyopharm Therapeutics, Lowers Price Target to $19
➖ NeutralBenzinga•Nov 4, 2025, 04:31 PM
Karyopharm Therapeutics Files Prospectus For Resale From Time To Time Of Up To 9.57M Common Stock By Selling Stockholders
➖ NeutralBenzinga•Nov 3, 2025, 10:18 PM
Karyopharm Therapeutics Affirms FY2025 Sales Guidance of $140.000M-$155.000M vs $149.328M Est
➖ NeutralBenzinga•Nov 3, 2025, 01:01 PM
Karyopharm Therapeutics Q3 EPS $(3.82) Misses $(3.13) Estimate, Sales $44.000M Beat $41.212M Estimate
➖ NeutralBenzinga•Nov 3, 2025, 12:32 PM
HC Wainwright & Co. Upgrades Karyopharm Therapeutics to Buy, Announces $15 Price Target
📈 PositiveBenzinga•Oct 13, 2025, 11:23 AM
Piper Sandler Reiterates Overweight on Karyopharm Therapeutics, Lowers Price Target to $12
➖ NeutralBenzinga•Oct 9, 2025, 02:17 PM
Baird Maintains Outperform on Karyopharm Therapeutics, Lowers Price Target to $21
📈 PositiveBenzinga•Oct 9, 2025, 12:08 PM
Karyopharm Therapeutics Says Top-Line Data From Phase 3 SENTRY Trial In Myelofibrosis On Track For March 2026
➖ NeutralBenzinga•Oct 8, 2025, 11:27 AM
Karyopharm Therapeutics Expects Q3 Preliminary Total Revenue Of $42M - $44M And U.S. XPOVIO Net Product Revenue Of ~$32M
➖ NeutralBenzinga•Oct 8, 2025, 11:23 AM
Karyopharm rises on securing $100M in financing to extend cash runway into Q2 2026
📈 PositiveSeeking Alpha•Oct 8, 2025, 11:18 AM
Karyopharm Therapeutics Says Top-Line Data From Phase 3 SENTRY Trial In Myelofibrosis Is On Track For March 2026
➖ NeutralBenzinga•Oct 8, 2025, 11:07 AM
Karyopharm Therapeutics Expects Q3 Preliminary Total Revenue And U.S. XPOVIO Net Product Revenue Of $42M - $44M And ~$32M, Respectively
➖ NeutralBenzinga•Oct 8, 2025, 11:06 AM
Karyopharm Secures $100M Of Financial Flexibility And Additional Capital To Extend Cash Runway Into Q2 2026
📈 PositiveBenzinga•Oct 8, 2025, 11:04 AM
Karyopharm Completes Enrollment In Phase 3 Trial Testing New Combo Therapy For Myelofibrosis Patients
📈 PositiveBenzinga•Sep 10, 2025, 11:02 AM
Frequently Asked Questions about KPTI
What is KPTI's current stock price?
Karyopharm Therapeutics Inc. (KPTI) is currently trading at $6.94 per share. The stock has moved +8.95% today.
What is the analyst price target for KPTI?
The average analyst price target for KPTI is $14.17, based on 1 analyst.
What sector is Karyopharm Therapeutics Inc. in?
Karyopharm Therapeutics Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is KPTI's market cap?
Karyopharm Therapeutics Inc. has a market capitalization of $0.06 billion, making it a small-cap company.
Does KPTI pay dividends?
No, Karyopharm Therapeutics Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorALGS
Aligos Therapeutics, Inc.
$10.68
Mkt Cap: $0.1B
BRNS
Barinthus Biotherapeutics plc
$0.74
Mkt Cap: $0.0B
CVM
CEL-SCI Corporation
$4.91
Mkt Cap: $0.0B
FGEN
FibroGen, Inc.
$8.60
Mkt Cap: $0.0B
INMB
INmune Bio, Inc.
$1.83
Mkt Cap: $0.0B
MDCX
Medicus Pharma Ltd. Common Stock
$1.69
Mkt Cap: $0.0B
MRSN
Mersana Therapeutics, Inc.
$28.94
Mkt Cap: $0.1B
SNTI
Senti Biosciences, Inc.
$1.20
Mkt Cap: $0.0B
TELO
Telomir Pharmaceuticals, Inc. Common Stock
$1.41
Mkt Cap: $0.0B
XFOR
X4 Pharmaceuticals, Inc.
$3.60
Mkt Cap: $0.0B
Explore stocks similar to KPTI for comparison